Comparison of Epidermal Growth Factor Receptor Mutation Statuses in Tissue and Plasma in Stage I–IV Non-Small Cell Lung Cancer Patients

Circulating DNA is a Useful Prognostic Factor in Patients with Advanced Non-small Cell Lung Cancer

(2011) Rafael Sirera et al.   Journal of Thoracic Oncology

Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer

(2011) Koichi Goto et al.   Journal of Thoracic Oncology

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

(2011) Caicun Zhou et al.   LANCET ONCOLOGY

The Applicability of a Predictive Index for Second- and Third-Line Treatment of Unselected Non-Small-Cell Lung Cancer Patients

(2011) Kamila Wojas-Krawczyk et al.   RESPIRATION

Low correspondence of EGFR mutations in tumor tissue and paired serum of non-small-cell lung cancer patients

(2010) Guo-hong Song et al.   Chinese Journal of Cancer Research

Quantification of Circulating Cell-Free DNA in the Serum of Patients with Obstructive Sleep Apnea–Hypopnea Syndrome

(2010) Liang Ye et al.   LUNG

Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors

(2010) Marie Brevet et al.   LUNG CANCER

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Single-Molecule Detection of Epidermal Growth Factor Receptor Mutations in Plasma by Microfluidics Digital PCR in Non-Small Cell Lung Cancer Patients

(2009) T. K.F. Yung et al.   CLINICAL CANCER RESEARCH

Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non-Small Cell Lung Cancer

(2009) Y. Kuang et al.   CLINICAL CANCER RESEARCH

Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer

(2009) Chen He et al.   INTERNATIONAL JOURNAL OF CANCER

Epidermal Growth Factor Receptor Mutations in Plasma DNA Samples Predict Tumor Response in Chinese Patients With Stages IIIB to IV Non–Small-Cell Lung Cancer

(2009) Hua Bai et al.   JOURNAL OF CLINICAL ONCOLOGY

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer

(2008) Massimiliano Paci et al.   LUNG CANCER